Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $50.0 million
Deal Type : Financing
Summit Announces Agreement For a Fundraising of Approximately $50 Million
Details : Funds support continued patient enrolment into the Ri-CoDIFy Phase 3 clinical trial program of ridinilazole for the treatment of Clostridium difficile infection; launch of Ridinilazole and Development of early-stage research projects using the Company’...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 02, 2020
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $50.0 million
Deal Type : Financing
Lead Product(s) : Docusate Potassium
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Quest Products, LLC
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Quest will add the Enemeez and DocuSol brands of bowel care products, to its' portfolio of self-care products.
Brand Name : Enemeez
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 24, 2020
Lead Product(s) : Docusate Potassium
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Quest Products, LLC
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
